Conditions: Kidney Neoplasms Carcinoma, Renal Cell Kidney (Renal Cell) Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 17
Healthy volunteers: no

Brief summary:
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).

Detailed description:
This is a single arm prospective trial in patients with newly-diagnosed advanced renal cell cancer (RCC) who were scheduled for sunitinib therapy and utilized an extensive panel of quantitative metrics on baseline and interim FDG PET/CT to evaluate the predictive utility of each of these measurements.

The objectives were to evaluate the FDG PET/CT measurement parameters for prediction of prognosis after sunitinib therapy in patients with RCC using histopathologic (post-therapy nephrectomy) or clinical follow-up for validation.

Arms:
arm 1: FDG PET CT F-18 Fluoro-deoxi-glucose: 15 mCi iv Gadolinium-DTPA: 0.1 mmol/kg Sunitinib: 50 mg/day po

Interventions: intervention 1: FDG PET CT intervention 2: DCE MRI intervention 3: F-18 Fluoro-deoxi-glucose intervention 4: Gadolinium-DTPA intervention 5: Sunitinib
Intervention descriptions: intervention 1: nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body intervention 2: DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg). intervention 3: 15 mCi iv intervention 4: 0.1 mmol/kg iv intervention 5: 50 mg/day po

Protocol document: